Author:
Kumar Prince,Meghvansi Mukesh K.,Kamboj D. V.
Abstract
AbstractShigella has the remarkable capability to acquire antibiotic resistance rapidly thereby posing a significant public health challenge for the effective treatment of dysentery (Shigellosis). The phage therapy has been proven as an effective alternative strategy for controlling Shigella infections. In this study, we illustrate the isolation and detailed characterization of a polyvalent phage 2019SD1, which demonstrates lytic activity against Shigella dysenteriae, Escherichia coli, Vibrio cholerae, Enterococcus saccharolyticus and Enterococcus faecium. The newly isolated phage 2019SD1 shows adsorption time < 6 min, a latent period of 20 min and burst size of 151 PFU per bacterial cell. 2019SD1 exhibits considerable stability in a wide pH range and survives an hour at 50 °C. Under transmission electron microscope, 2019SD1 shows an icosahedral capsid (60 nm dia) and a 140 nm long tail. Further, detailed bioinformatic analyses of whole genome sequence data obtained through Oxford Nanopore platform revealed that 2019SD1 belongs to genus Hanrivervirus of subfamily Tempevirinae under the family Drexlerviridae. The concatenated protein phylogeny of 2019SD1 with the members of Drexlerviridae taking four genes (DNA Primase, ATP Dependent DNA Helicase, Large Terminase Protein, and Portal Protein) using the maximum parsimony method also suggested that 2019SD1 formed a distinct clade with the closest match of the taxa belonging to the genus Hanrivervirus. The genome analysis data indicate the occurrence of putative tail fiber proteins and DNA methylation mechanism. In addition, 2019SD1 has a well-established anti-host defence system as suggested through identification of putative anti-CRISPR and anti-restriction endonuclease systems thereby also indicating its biocontrol potential.
Publisher
Springer Science and Business Media LLC
Reference76 articles.
1. Zaidi, M. B. & Estrada-García, T. Shigella: A highly virulent and elusive pathogen. Curr. Trop. Med. Rep. 1(2), 81–87. https://doi.org/10.1007/s40475-014-0019-6 (2014).
2. WHO. State of art of new vaccine research and development. Document No. WHO/IVB/06.01 (2006). World Health Organization.www.who.int/vaccines-documents/ (Accessed 26 July 2020).
3. Khalil, I. A. et al. Morbidity and mortality due to Shigella and enterotoxigenic Escherichia coli diarrhoea: The Global Burden of Disease Study 1990–2016. Lancet Infect. Dis. 18, 1229–1240. https://doi.org/10.1016/S1473-3099(18)30475-4 (2018).
4. Phalipon, A. & Sansonetti, P. J. Shigella’s ways of manipulating the host intestinal innate and adaptive immune system: A tool box for survival?. Immunol. Cell Biol. 85(2), 119–129. https://doi.org/10.1038/sj.icb7100025 (2007).
5. Dutta, P. et al. Clinical presentation of shigellosis during the 1984 epidemic of bacillary dysentery in West Bengal. J. Assoc. Physicians India 35, 195–197 (1987).
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献